Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids
Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids
复制标题
DOI：
10.1136/ard.2005.049924
复制
发表时间：
2006-11-01
影响因子：
27.4
通讯作者：
Gutierrez, C.
中科院分区：
文献类型：
--
作者：
Suarez, A.;Lopez, P.;Gutierrez, C.
目的：目的：检测系统性红斑狼疮（SLE）患者外周血中CD4+ CD25+ T细胞的数量，探讨SLE患者治疗和临床表现对CD4+ T细胞数量的影响。对56例正常人和110例SLE患者的外周血淋巴细胞亚群进行了检测。数据与过去3个月的治疗和各种临床表现有关。对照组的CD4+ CD25（高）淋巴细胞表达低水平的CD69、CD154或CD30，但也表达糖皮质激素诱导的肿瘤坏死因子受体、高水平的细胞内细胞毒素T淋巴细胞相关抗原4、CD45 RO和减少量的CD4，所有这些都是天然调节性T细胞的表型特征。另一方面，CD4+ CD25（低）细胞表达最高水平的活化标志物，表明它们代表最近活化的效应细胞。类似地，对SLE患者的细胞分析显示了相同的两个表型可区分的CD4+ CD25（低）和CD4+ CD25（高）群体，尽管两者表达的活化标志物水平略有增加。定量分析显示，与对照组相比，SLE患者的CD25（低），尤其是CD25（高）细胞的百分比显著升高。这种增加与临床表现无关，但与糖皮质激素治疗有关。糖皮质激素治疗的患者提出了升高的水平的CD25（高）细胞，而未经治疗的患者和那些抗疟疾或免疫抑制药物的水平相似，在controls.Conclusions：的百分比CD4+ CD25（高）细胞没有改变在非类固醇治疗的患者，而糖皮质激素治疗增加了他们的频率在SLE患者。
Objectives: To characterise and quantify the CD4+ CD25+ T cell population in patients with systemic lupus erythematosus (SLE) and to detect the possible influence of treatments and clinical manifestations.Methods: Characterisation of CD25(low) and CD25(high) CD4+ T cells from healthy controls and from patients with SLE was carried out using flow cytometry, analysing the expression of activation and differentiation markers. The percentage of both circulating cell subsets was determined in 56 controls and 110 unselected patients with SLE. Data were related to treatment during the past 3 months and to various clinical manifestations.Results: CD4+ CD25(high) lymphocytes from controls expressed low levels of CD69, CD154 or CD30, but also expressed glucocorticoid-induced tumour necrosis factor receptor, high levels of intracellular cytotoxin T lymphocyte-associated antigen 4, CD45RO and diminished amounts of CD4, all of which are phenotypic characteristics of natural regulatory T cells. CD4+ CD25(low) cells, on the other hand, expressed the highest levels of activation markers, indicating that they represent recently activated effector cells. Similarly, analysis of cells from patients with SLE showed the same two phenotypically distinguishable CD4+ CD25(low) and CD4+ CD25(high) populations, although both expressed slightly increased levels of activation markers. Quantitative analysis showed a considerably raised percentage of CD25(low) and, especially, CD25(high) cells in patients with SLE compared with controls. This increment was unrelated to clinical manifestations, but correlated with glucocorticoid treatment. Patients treated with glucocorticoids presented raised levels of CD25(high) cells, whereas untreated patients and those with anti-malarial or immunosuppressive drugs had levels similar to those in controls.Conclusions: The percentage of CD4+ CD25(high) cells was not altered in non-steroid-treated patients, whereas glucocorticoid treatment increased their frequency in patients with SLE.